Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/07—Tetrapeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B5/00—Measuring for diagnostic purposes; Identification of persons
  • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
  • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/06—Tripeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/32—Alcohol-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/34—Tobacco-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/36—Opioid-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/06—Antiglaucoma agents or miotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• NMDAR N-mcthyi-D-aspartate receptor
• the NMDAR is activated by the binding of NMDA, glutaniate (Glu), and aspartate (Asp). It is competitively antagonized by D-2-ammo-5-phosphonovalerate (D-AP5; D-APV), and non-competitively antagonized by phenylcyciidine (PCP), and MK-801.
• D-AP5 D-2-ammo-5-phosphonovalerate
• PCP phenylcyciidine
• MK-801 MK-801.
• the NMDAR is co-activated by glycine (Gly) ( ozikowski et al, 1990, Journal of Medicinal Chemistry 33: 1561 -1571).
• Gly ozikowski et al, 1990, Journal of Medicinal Chemistry 33: 1561 -1571.
• the binding of glycine occurs at an allosteric regulatory site on the NMDAR complex, and this increases both the duration of channel open time, and the frequency of the opening of the NMDAR
• NMD A-niodulating small molecule agonist and antagonist compounds have been developed for potential therapeutic use.
• recent human clinical studies have identified NMDAR as a novel target of high interest for treatment of depression.
• These studies conducted using known NMDAR antagonists CPC- 101 ,606 and ketamine have shown significant reductions in the Hamilton Depression Rating Score in patients suffering with refractory depression.
• the efficacy was significant, the side effects of sing these NDMAR antagonists were severe.
• Such compounds may also have utility for learning or for treatment of cognitive disorders.
• GLYX-13 an improved partial agonist of NMDAR, termed as GLYX-13.
• GLYX-13 exhibits nootropic, neuroprotective and antinociceptive activity, and enhances learning, memory and cognition in vivo, GLYX-13, has also been shown to exhibit rapid-acting, robust, and sustained antidepressant activity and to lack the pvschotomimetic side effects associated with other drugs and mechanisms that target the NMD A receptor.
• the present disclosure relates in part to methods of treating a cognitive disorder or enhancing cognitive function and/or learning in a patient in need thereof, comprising: generating a MRI signal that is a measurement of brain activity in a patient; identifying the signal as a. normal or abnormal brain state of the patient; and administering to the patient an effective amount of a NMDAR partial agonist, e.g., GLYX- 13, based on the signal identification.
• a NMDAR partial agonist e.g., GLYX- 13, based on the signal identification.
• Some embodiments can include one or more of the following features, which can further be combined with one or more other features disclosed herein.
• Generating an MRI signal can include using functional magnetic resonance imaging, e.g., the functional magnetic resonance imaging can include blood-oxygen-level dependent contrast imaging.
• the brain activity can be neural activation, e.g., neural activation in learning and/or memory related regions of the brain.
• a. method for identifying a biomarker related to neural activation, learning, or memory or identifying a patient population who is more susceptible to such disorders, comprising administering a NMDAR partial agonist, e.g., GLYX-13 to a subject (e.g., an animal, e.g., human or rodent); imaging the animal using functional magnetic resonance to create measurable activity such as blood oxygen levels; analyzing the activity; and identifying the biomarker as result of the activity.
• a subject e.g., an animal, e.g., human or rodent
• functional magnetic resonance to create measurable activity
• Using functional magnetic resonance to create measurable activity can include using bl ood-ox gen-level dependent contrast imaging.
• the measurable activity can include changes in blood flow and/or blood oxidation in one or more regions of the brain in the animal.
• the biomarker can be a blood-oxygen-level dependent contrast signal in one or more regions of the brain in the animal.
• the method can further include associating a patient or subpopulation of patients with the biomarker.
• the method can further include one or both of the following: (a) determining whether GLYX-13 would be therapeutically effective for treating a. cognitive or mental disorder; and (b) determining susceptibility/receptivity in patient or a subpopulation of patients suffering from a cognitive or mental disorder (e.g., depression, e.g., refractory depression).
• a cognitive or mental disorder e.g., depression, e.g., refractory depression
• a disorder selected from the group consisting of epilepsy, AIDS dementia, multiple system atrophy, progressive supranuclear palsy, Friedrich's ataxia, autism, fragile X syndrome, tuberous
• SAD Seasonal affective disorder
• mood disorder depressions caused by chronic medical conditions such as cancer or chronic pain, chemotherapy, chronic stress, Bipolar disorder, and manic depressive disorder, in a patient in need thereof, comprising:
• Generating an MRl signal can include using functional magnetic resonance imaging, e.g., the functional magnetic resonance imaging can include blood-oxygen-level dependent contrast imaging.
• Bipolar disorder, and manic depressive disorder or identifying a patient population who is more susceptible to such disorders, comprising administering a.
• NMD ARpartial agonist e.g., GLYX-13
• a subject e.g., an animal, e.g., human or rodent
• functional magnetic resonance to create measurable activity such as blood oxygen levels
• analyzing the activity e.g., human or rodent
• identifying the biomarker as result of the activity e.g., a subject
• Some embodiments can include one or more of the following features, which can further be combined with one or more other features disclosed herein.
• Using functional magnetic resonance to create measurable activity can include using blood-oxygen-level dependent contrast imaging.
• the measurable activity can include changes in blood flow and/or blood oxidation in one or more regions of the brain in the animal.
• the biomarker cars be a blood-oxygen-level dependent contrast signal in one or more regions of the brain in the animal.
• the method can further include associating a patient or subpopulation of patients with the biomarker.
• the method can further include one or both of the following: (a) determining whether GLYX-13 would be
• a method for tracking treatment progress and/or treatment endpoints in a patient suffering from a cognitive or mental disorder comprising generating a MRI signal that is a measurement of brain activity in a patient; identifying the signal as a normal or abnormal brain state of the patient: and administering to the patient an effective amount of GLYX-13 based on the signal identification.
• Generating an MR] signal can include using functional magnetic resonance imaging, e.g., the functional magnetic resonance imaging can include blood-oxygen-level dependent contrast imaging.
• FIG. 1 is a flow diagram summarizing the study design for the study described in Example 2.
• FIG. 2 is a flow diagram summarizing the study flow for the study described in Example 2.
• FIG. 3 is a diagram that summarizes the design of the item category association task used in the study described in Example 2.
• FIG. 4 is a diagram that summarizes the second level fixed effects analyses performed in the study described in Example 2.
• FIG. 5 is a graph showing that GLYX-13 and Placebo treated subjects show a robust and comparable learning effect across cycle.
• FIG. 6 provides a series of fMRI images of regions showing significant change in BOLD activation across learning cycles.
• FIGS. 7A-7F provide a series of fMRI images of regions showing that among identified regions, six demonstrated significant group by cycle interaction effects on extracted mean % signal change, all of which demonstrated enhanced activation among GLYX-13 vs. Placebo treated individuals.
• the present disclosure relates in part to methods for identifying a biomarlcer related to neural activation, learning, or memor ' or identifying a patient population who is more susceptible to such disorders, comprising administering GLYX-13 to an animal; imaging the animal using functional magnetic resonance to create measurable activity such as blood oxygen levels: analyzing the activity, and identifying the biomarker as result of the activity.
• Functional magnetic resonance imaging or functional MR! (fMRI) is a functional neuroimaging procedure using MR] technology that measures brain activity by defecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area, of the brain is in use, blood flow to that region also increases.
• iMRI uses the Blood-oxygen-level dependent (BOLD) contrast.
• BOLD Blood-oxygen-level dependent
• fMRI can in some embodiments, also be combined and complemented with other measures of brain physiology such as EEG and MRS. Other methods may largely use biomarkers other than the BOLD signal.
• Contemplated methods include a methods of treating, or method of identifying biomarkers of , autism and/or an autism spectrum disorder.
• patients suffering from autism also suffer from another medical condition, such as Fragile X syndrome, tuberous sclerosis, congenital rubella syndrome, and untreated phenylketonuria.
• methods of treating, or method of identifying biomarkers of, wherein the disorder is selected from group consisting of: epilepsy, AIDS dementia, multiple system atrophy, progressive supra-nuclear palsy, Friedrielrs ataxia, autism, fragile X syndrome, tuberous sclerosis, attention deficit disorder, olivio-poiito-cerebcllar atrophy, cerebral palsy, drug-induced optic neuritis, peripheral neuropathy, myelopathy, ischemic retinopathy, glaucoma, cardiac arrest, behavior disorders, and impulse control disorders that includes administering an identified compound.
• epilepsy AIDS dementia, multiple system atrophy, progressive supra-nuclear palsy, Friedrielrs ataxia, autism, fragile X syndrome, tuberous sclerosis, attention deficit disorder, olivio-poiito-cerebcllar atrophy, cerebral palsy, drug-induced optic neuritis, peripheral neuropathy, myelopathy, ischemic retinopathy, glaucoma
• contemplated herein are methods of treating or identifying biomarkers related to attention deficit disorder, ADHD (attention deficit hyperactivity disorder), schizophrenia, anxiety, amelioration of opiate, nicotine and/or ethanol addiction (e.g., method of treating such addiction or ameliorating the side effects of withdra wing from such addiction), spinal cord injury diabetic retinopathy, traumatic brain injury, post-traumatic stress syndrome and/or Huntington 's chorea, in a patient in need thereof or identifying a biomarker for one or more of these disorders, that includes administering an identified compound.
• ADHD attention deficit hyperactivity disorder
• schizophrenia e.g., anxiety, amelioration of opiate, nicotine and/or ethanol addiction
• spinal cord injury diabetic retinopathy e.g., traumatic brain injury, post-traumatic stress syndrome and/or Huntington 's chorea
• patients suffering from schizophrenia, addiction e.g.
• disclosed methods relate to Alzheimer's disease, or e.g., treatment of memory loss that e.g., accompanies early stage Alzheimer's disease.
• disclosed methods may relate to common depression conditions including Major Depressive Disorder and Dysthymic Disorder. Other depression conditions develop under unique circumstances.
• Such depression conditions include but are not limited to Psychotic depression, Postpartum depression, Seasonal affective disorder (SAD), mood disorder, depressions caused by chronic medical conditions such as cancer or chronic pain, chemotherapy, chronic stress, post traumatic stress disorders, and Bipolar disorder (or manic depressive disorder).
• SAD Seasonal affective disorder
• mood disorder depressions caused by chronic medical conditions such as cancer or chronic pain, chemotherapy, chronic stress, post traumatic stress disorders, and Bipolar disorder (or manic depressive disorder).
• Refractory depression occurs in patients suffering from depression who are resistant to standard
• pharmacological treatments including tricyclic antidepressants, MAOIs, SSRJs, and double and triple uptake inhibitors and/or anxiolytic drugs, as well non-pharmacological treatments such as psychotherapy, electroconvulsive therapy, vagus nerve stimulation and/or transcranial magnetic stimulation.
• Treatment resistant-patient or animals e.g. humans are contemplated for treatment or identified as one who fails to experience alleviation of one or more symptoms of depression (e.g., persistent anxious or sad feelings, feelings of helplessness, hopelessness, pessimism) despite undergoing one or more standard pharmacological or non-pharmacological treatment.
• a treatment-resistant patient is one who fails to experience alleviation of one or more symptoms of depression despite undergoing treatment with two different antidepressant drugs. In other embodiments, a treatment-resistant patient is one who fails to experience alleviation of one or more symptoms of depression despite undergoing treatment with four different antidepressant drugs.
• a treatment-resistant patient may also be identified as one who is unwilling or unable to tolerate the side effects of one or more standard pharmacological or non-pharmacological treatment.
• methods for treating refractory depression by administering an effective amount of an identified compound to a treatment- resistant patient in need thereof are contemplated. In an embodiment, methods of treating depression is contemplated when a patient has suffered depression for e.g. 5, 6, 7, 8 or more weeks, or for a month or more. .
• methods of treating a disorder in a patient need thereof are contemplated, wherein the disorder is selected from group consisting of: epilepsy, AIDS dementia, multiple system atrophy, progressive supra-nuclear palsy, Friedrich's ataxia, autism, fragile X syndrome, tuberous sclerosis, attention deficit disorder, olivio-ponto-cerebellar atrophy, cerebral palsy, drug-induced optic neuritis, peripheral neuropathy, myelopathy, ischemic retinopathy, glaucoma, cardiac arrest, behavior disorders, and impulse control disorders that includes administering an identified compound.
• epilepsy AIDS dementia, multiple system atrophy, progressive supra-nuclear palsy, Friedrich's ataxia, autism, fragile X syndrome, tuberous sclerosis, attention deficit disorder, olivio-ponto-cerebellar atrophy, cerebral palsy, drug-induced optic neuritis, peripheral neuropathy, myelopathy, ischemic retinopathy, glaucoma, cardiac arrest, behavior disorders, and impulse
• Treating ' ' includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder and the like.
• “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
• the term "effective amount” refers to an amount of the subject component, e.g., GLYX-13 (or a composition containing GLYX-13) that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher,
• GLYX peptide refers to a peptide having MDAR glycine - site partial agonist/antagonist activity. GLYX peptides may be obtained by well-known recombinant or synthetic methods such as those described in US Patents 5,763,393 and
• GLYX refers to a
• candidate compounds have the same microarray results as GLYX-13 and/or the below compounds.
• GLYX-13 refers to the compound depicted as:
• GLYX 13 polymorphs, homologs, hydrates, solvates, free bases, and/or suitable salt forms of GLYX 13 such as, but not limited to, the acetate salt.
• the peptide may he cyclyzed or non-cyclyzed form as further described in US 5,7(53,393.
• an a GLY X- 13 analog may include an insertion or deletion of a moiety on one or more of the Thr or Pro groups such as a deletion of CH?, OH, or ' NH 2 moiety.
• GLYX-13 may be optionally substituted with one or more halogens, Cj-C 3 alkyl (optionally substituted with halogen or amino), hydroxyl, and'Or amino.
• Glycine-site partial agonist of the NMDAR are disclosed in US 5,7(53,393, US (5,107,271, and Wood et al, NeuroReport, 19, 1059-10(51 , 2008, the entire contents of which are herein incorporated by reference,
• a therapeutically effective amount of GLYX-13 can be in the range of from about 0.01 mg/kg to about 1000 mg/kg per administration (e.g., about 0.01 mg/kg to about 100 mg/kg, about 0.01 mg kg to about 50 mg/kg, about 0.01 mg kg to about 25 mg/kg, about 0.01 mg/kg to about 10 mg/kg, about 0.1 mg/kg to about 100 mg/kg, about 0.1 mg/kg to about 50 mg/kg, about 0.1 mg/kg to about 50 mg/kg, about 0.1 mg/kg to about 10 mg kg, about 1 mg/kg to about 100 mg kg, about 1 mg/kg to about 50 mg/kg, about 1 mg kg to about 50 mg/kg per day, about 1 mg/kg to about 10 mg/kg, or about 1 mg kg to about 10 mg/kg per administration, e.g., once a week, twice a week or three times a week and'Or as described anywhere herein).
• the dosage of GLYX-13 may be at any dosage including, but not limited to, about 1 ug kg. 25 ug/kg, 50 ug/kg, 75 ug/kg, 100 u ug/kg, 125 ug/kg, 150 ug/kg, 175 ug/kg, 200 ug/kg, 225 ug/kg, 250 ug/kg, 275 ug/kg, 300 ug/kg, 325 ug/kg, 350 ug/kg, 375 ug/kg, 400 ug/kg, 425 ug/kg, 450 ug/kg, 475 ug/kg, 500 ug/kg, 525 ug/kg, 550 ug/kg, 575 ug/kg, 600 ug/kg, 625 ug/kg, 650 ug kg, 675 ug/kg, 700 ug kg, 725 ug/kg, 750 ug/kg, 7
• GLYX-13 may be therapeutically effective with a range (e.g., an intravenous dose range) of about 1 to about 10 mg/kg, e.g., about 5 to aboutlO mg/kg, e.g. about 1 mg/kg, about 5 mg/kg, or about lOmg/kg.
• a range e.g., an intravenous dose range
• any of the GLYX-13 dosages described herein can be administered on a less than daily basis, e.g., every other day (e.g., every two days); one or two times a week: one, two or three times a week; two or three times a week; twice weekly (e.g. every 3 days, every 4 days, every 5 days, every 6 days or e.g. administered with an interval of about 2 to about 3 days between doses): every three to four days; once a week; once every two weeks (bi-weekly); twice monthly; once a month, once every two months, once every thre months, once every four months, once every five months, once every six months, or even less often.
• GLYX-13 is administered at a frequency of once a week, twice a week, once every two weeks, or any combination thereof.
• GLYX-13 is administered at a range (e.g., an intravenous dose range) of about I to about 10 mg/kg, e.g., about 5 to about 10 mg/kg, e.g. about I mg/kg, about 5 mg/kg, or about l Omg/kg, and/or GLYX-13 is administered at a frequency of once a week, once every two weeks, or any combination thereof.
• a range e.g., an intravenous dose range
• the present disclosure contemplates "combination therapy,” which includes (but is not limited to ) co-administering an effective amount of GLYX- 13 and one or more other biologically active agents (e.g., one or more other anti-depressant agents) as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents.
• the beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents.
• Combination therapy is intended to embrace administration of multiple therapeu tic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner.
• Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single tablet or capsule or i.v. solution having a fixed ratio of each therapeutic agent or in multiple, single tablets, capsules, or i.v. solutions for each of the therapeutic agents.
• Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues.
• the therapeutic agents can be administered by the same route or by different routes.
• a first therapeutic agent e.g., GLYX -13
• the other therapeutic agents of the combination may be administered orally.
• all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection.
• GLYX-13 as well as any other pharmacological agent (e.g., one or more other antidepressant agents) of the present invention may be administered by various means, depending on their intended use, as is well known in the art.
• compositions of the present invention may be formulated as tablets, capsules, granules, powders or syrups.
• formulations of the present invention may be administered parenterally as injections (intravenous, intramuscular or subcutaneous), drop infusion preparations, or suppositories.
• compositions may be prepared by conventional means, and, if desired, the compositions may be mixed with any conventional additive, such as an exeipient, a binder, a disintegrating agent, a lubricant, a corrigeni a solubilizing agent, a suspension aid, an emulsifying agent or a coating agent.
• any conventional additive such as an exeipient, a binder, a disintegrating agent, a lubricant, a corrigeni a solubilizing agent, a suspension aid, an emulsifying agent or a coating agent.
• GLYX-13 herein may be administered parenterally to a patient including, but not limited to, subcutaneous! ⁇ ' and intravenously.
• one or more of the components of the combinations described herein may also be administered via slow controlled i.v. infusion or by release from an implant device.
• wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants may be present in the formulated agents.
• Subject compositions may be suitable for oral, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration.
• the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
• the amount of composition that may be combined with a carrier material to produce a single dose vary depending upon the subject being treated, and the particular mode of admin istrati o ,
• Methods of preparing these formulations include the step of bringing into association compositions of the present invention with the carrier and, optionally, one or more accessory ingredients.
• the formulations are prepared by uniformly and intimately bringing into association agents with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
• Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragaeanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia), each containing a predetermined amount of a subject composition thereof as an active ingredient.
• Compositions of the present invention may also be administered as a bolus, electuary, or paste,
• the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example,
• compositions may also comprise buffering agents.
• Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such ex dpi en ts as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
• a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
• Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylrnethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
• Molded tablets may be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent.
• Tablets, and other solid dosage forms may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art, [0044]
• Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
• the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof,
• inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl
• Suspensions in addition to the subject composition, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethyiene sorbitol and sorbitan esters, macrocrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
• suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethyiene sorbitol and sorbitan esters, macrocrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
• compositions of this invention suitable for parenteral administration comprise a subject composition in combination with one or more phannaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacterio stats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
• “Pharmaceutically or pharmacologically acceptable” include molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate. For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologies standards.
• pharmaceutically acceptable carrier or “pharmaceutically acceptable excipient” as used herein refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The combinations described herein may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
• aqueous and non-aqueous carriers examples include water, efhanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and eyelodcxt iiis.
• efhanol such as glycerol, propylene glycol, polyethylene glycol, and the like
• vegetable oils such as olive oil
• injectable organic esters such as ethyl oleate and eyelodcxt iiis.
• Proper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants,
• Disclosed compounds may be provided as part of a liquid or solid formulation, for example, aqueous or oily suspensions, solutions, emulsions, syrups, and/or elixirs.
• the compositions may also be formulated as a dry product for constitution with water or other suitable vehicle before use.
• Such liquid preparations may contain additives including, but not limited to, suspending agents, emulsifying agents, nonaqueous vehicles and preservatives.
• Suspending agent include, but are not limited to, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats.
• Emulsifying agents include, but are not limited to, lecithin, sorbitan monooleate, and acacia.
• Nonaqueous vehicles include, but are not limited to, edible oils, almond oil, fractionated coconut oil, oily esters, propylene glycol, and ethyl alcohol.
• Preservatives include, but are not limited to, methyl or propyl hydroxybenzoate and sorbic acid.
• Contemplated compounds may also be formulated for parenteral administration including, but not limited to, by injection or continuous infusion.
• Formulations for injection may be in the form of suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents including, but not limited to, suspending, stabilizing, and dispersing agents.
• the composition may also be provided in a powder form for reconstitution with a suitable vehicle including, but not limited to, sterile, pyrogen-free water.
• Inclusion Criteria The inclusion criteria for adult subjects participating in the study were as follows (i) 18— 40 years of age; (ii) estimated IQ within what is considered to be the normal range (80-120); and (iii) no personal medical, neurologic, or psychiatric history, or reported history of psychiatric il lness amon g first degree relatives.
• Study Design (randomized, single-blind, parallel group). A flow chart showing the study design is shown in FIG. 1 , After initial (Visit 1), patients were randomized to either single IV administration of GLYX-13 (5 mg kg) or placebo on subsequent visit (Visit 2). fM l studies started within 20 minutes post-infusion. Subjects returned approximately one week after Visit 2 to complete behavioral tasks in scanner and assess any adverse effects. The study flow is shown in FIG. 2, and the subject characteristics are summarized in Table 1.
• Item Category Association Task see, e.g., Onur OA, Schlaepfer TE, Rukolja J, Bauer A, Jeung H, Patin A, Otte D-M, Shah NJ, Maier W, Kendrick KM, Fink GR, Hurleman R (2010).
• the N-methyl-D-aspartate receptor co-agonist D-Cycloserine facilitates declarative learning and hippocampal activity in humans. Biol. Psychiatry, 67, 1205).
• Subjects were asked to learn arbitrary group membership (A or B) of 3-digit numbers. Visual feedback was provided immediately following choice (button press) to indicate correct item category association. There were eight category memberships to be learned, which were presented over eight cycles (i.e., 7 repetitions) for a total of 64 tiials per ran; three sets of learning runs (each with different 3-digit number sets. See FIG. 3.
• FIG 6 provides a series of fMRI images of regions showing significant change in BOLD activation across learning cycles.
• FIGS. 7A-7F provide a series of fMRI images of regions showing that among identified regions, si demonstrated significant group by cycle interaction effects on extracted mean % signal change, all of which demonstrated enhanced activation among GLYX-13 vs. Placebo treated individuals.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Psychiatry (AREA)
• Addiction (AREA)
• Physics & Mathematics (AREA)
• Radiology & Medical Imaging (AREA)
• Epidemiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Ophthalmology & Optometry (AREA)
• Pain & Pain Management (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pathology (AREA)
• High Energy & Nuclear Physics (AREA)
• Medical Informatics (AREA)
• Molecular Biology (AREA)
• Surgery (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Biophysics (AREA)
• Cardiology (AREA)
• Psychology (AREA)
• Hospice & Palliative Care (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Urology & Nephrology (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (2)

Family

ID=53371976

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (2)

Family Cites Families (8)

• 2014
  • 2014-12-15 US US15/104,223 patent/US20160345855A1/en not_active Abandoned
  • 2014-12-15 EP EP20174673.2A patent/EP3721799A1/en not_active Withdrawn
  • 2014-12-15 EP EP14870211.1A patent/EP3079579A4/en not_active Withdrawn
  • 2014-12-15 CN CN201480068036.1A patent/CN106102762A/zh active Pending
  • 2014-12-15 MX MX2016007716A patent/MX2016007716A/es unknown
  • 2014-12-15 CN CN202010314939.0A patent/CN111920412A/zh active Pending
  • 2014-12-15 JP JP2016538538A patent/JP2017500306A/ja active Pending
  • 2014-12-15 WO PCT/US2014/070340 patent/WO2015089503A2/en not_active Ceased
  • 2014-12-15 CA CA2933372A patent/CA2933372A1/en not_active Abandoned
  • 2014-12-15 AU AU2014361822A patent/AU2014361822A1/en not_active Abandoned
• 2016
  • 2016-06-09 IL IL246148A patent/IL246148A0/en unknown
• 2019
  • 2019-08-26 JP JP2019153406A patent/JP2020007333A/ja active Pending
  • 2019-11-13 AU AU2019264583A patent/AU2019264583A1/en not_active Abandoned
• 2020
  • 2020-08-02 IL IL276431A patent/IL276431A/en unknown

Also Published As

Similar Documents

Legal Events